IDO1 and neoplasm: Taken together, these findings corroborated that Epacasome-2 remained stable during circulation and provide superior tumour delivery potential, while facilitating timely release of EPA with deep and uniform tumour penetration and distribution, which are pivotal properties for in vivo EPA-mediated IDO1 inhibitory therapeutic delivery.